Nkarta (NKTX) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $81.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | RTSN |
|---|---|---|
| Share price | $1.14 | $10.51 |
| Market cap | $81.29M | $87.57M |
| 1-day change | +1.34% | -19.22% |
| YTD return | -38.65% | — |
| 1-year return | -36.94% | — |
| 5-year return | -93.05% | — |
| EPS (TTM) | $-1.73 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-104.08M | — |
| 52-week high | $3.72 | $18.64 |
| 52-week low | $1.11 | $9.23 |
| Distance from 52-week high | -69.49% | -43.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +825.11% | +391.63% |
| Average volume | 1.02M | 144.93K |
| Shares outstanding | 71.62M | 8.33M |
| Employees | 108 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NKTX vs RTSN FAQ
Which is bigger, Nkarta or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $81.29M for Nkarta (NKTX).
Are Nkarta and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.